REFERENCES
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
3. Cancer Australia. Ovarian cancer statistics in Australia. Available from: https://www.canceraustralia.gov.au/cancer-types/ovarian-cancer/ovarian-cancer-statistics-australia. [Last accessed on 5 Jan 2025].
5. Mazidimoradi A, Momenimovahed Z, Allahqoli L, et al. The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Sci Rep. 2022;5:e936.
6. Mandel P, Metais P. [Nuclear acids in human blood plasma]. C R Seances Soc Biol Fil. 1948;142:241-3.
7. Ivanov M, Baranova A, Butler T, Spellman P, Mileyko V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics. 2015;16 Suppl 13:S1.
8. Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142:199-205.
9. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015;9:358-67.
10. Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289:3869-75.
11. Chetty VK, Ghanam J, Anchan S, et al. Efficient small extracellular vesicles (EV) isolation method and evaluation of EV-associated DNA role in cell-cell communication in cancer. Cancers. 2022;14:2068.
12. Katsman E, Orlanski S, Martignano F, et al. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. Genome Biol. 2022;23:158.
13. Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer. Cancer Inform. 2022;21:11769351221076062.
14. Sebire E, Rodrigo CH, Bhattacharya S, Black M, Wood R, Vieira R. The implementation and impact of non-invasive prenatal testing (NIPT) for Down’s syndrome into antenatal screening programmes: a systematic review and meta-analysis. PLoS One. 2024;19:e0298643.
15. Romero R. A profile of Dennis Lo, DM, DPhil, FRCP, FRCPath, FRS. Am J Obstet Gynecol. 2018;218:371-8.
16. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-7.
17. Jamshidi A, Liu MC, Klein EA, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022;40:1537-49.e12.
18. Basharat S, Horton J. Emerging multi-cancer early detection technologies: CADTH horizon scan. Ottawa (ON); 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK598992/. [Last accessed on 5 Jan 2025].
19. Tsering T, Nadeau A, Wu T, Dickinson K, Burnier JV. Extracellular vesicle-associated DNA: ten years since its discovery in human blood. Cell Death Dis. 2024;15:668.
20. Song P, Wu LR, Yan YH, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022;6:232-45.
21. Sakamoto Y, Sereewattanawoot S, Suzuki A. A new era of long-read sequencing for cancer genomics. J Hum Genet. 2020;65:3-10.
22. Zhang Y, Zhao L, Li Y, et al. Advanced extracellular vesicle bioinformatic nanomaterials: from enrichment, decoding to clinical diagnostics. J Nanobiotechnology. 2023;21:366.
23. Jia Y, Yu L, Ma T, et al. Small extracellular vesicles isolation and separation: current techniques, pending questions and clinical applications. Theranostics. 2022;12:6548-75.
24. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180.
25. Lázaro-Ibáñez E, Sanz-Garcia A, Visakorpi T, et al. Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate. 2014;74:1379-90.
26. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24:766-9.
27. Lázaro-Ibáñez E, Lässer C, Shelke GV, et al. DNA analysis of low- and high-density fractions defines heterogeneous subpopulations of small extracellular vesicles based on their DNA cargo and topology. J Extracell Vesicles. 2019;8:1656993.
28. Baysa A, Fedorov A, Kondratov K, et al. Release of mitochondrial and nuclear DNA during on-pump heart surgery: kinetics and relation to extracellular vesicles. J Cardiovasc Transl Res. 2019;12:184-92.
29. Vagner T, Spinelli C, Minciacchi VR, et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018;7:1505403.
30. Qian Y, Hong X, Yu Y, et al. Characterization and functional analysis of extrachromosomal circular DNA discovered from circulating extracellular vesicles in liver failure. Clin Transl Med. 2024;14:e70059.
31. Guescini M, Genedani S, Stocchi V, Agnati LF. Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J Neural Transm. 2010;117:1-4.
32. Tsilioni I, Theoharides TC. Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA, and stimulate human microglia to secrete IL-1β. J Neuroinflammation. 2018;15:239.
33. Takenaga K, Koshikawa N, Nagase H. Intercellular transfer of mitochondrial DNA carrying metastasis-enhancing pathogenic mutations from high- to low-metastatic tumor cells and stromal cells via extracellular vesicles. BMC Mol Cell Biol. 2021;22:52.
34. Jin Y, Chen K, Wang Z, et al. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016;16:753.
35. Yokoi A, Villar-Prados A, Oliphint PA, et al. Mechanisms of nuclear content loading to exosomes. Sci Adv. 2019;5:eaax8849.
36. Liu H, Tian Y, Xue C, Niu Q, Chen C, Yan X. Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. J Extracell Vesicles. 2022;11:e12206.
37. Takahashi A, Okada R, Nagao K, et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat Commun. 2017;8:15287.
38. Reis-Sobreiro M, Chen JF, Novitskaya T, et al. Emerin deregulation links nuclear shape instability to metastatic potential. Cancer Res. 2018;78:6086-97.
39. Lian Q, Xu J, Yan S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017;27:784-800.
40. Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell. 2019;177:428-45.e18.
41. Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol. 2019;71:1000-11.
42. Elzanowska J, Berrocal L, García-Peláez B, et al. Defining optimal conditions for tumor extracellular vesicle DNA extraction for mutation profiling. Cancers. 2022;14:3258.
43. Ding T, Diao Y, Zeng X, et al. Influential factors on urine EV DNA methylation detection and its diagnostic potential in prostate cancer. Front Genet. 2024;15:1338468.
44. Nguyen B, Meehan K, Pereira MR, et al. A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Sci Rep. 2020;10:6083.
45. Nguyen B, Wong NC, Semple T, et al. Low-coverage whole-genome sequencing of extracellular vesicle-associated DNA in patients with metastatic cancer. Sci Rep. 2021;11:4016.
46. Li Y, Guo X, Guo S, et al. Next generation sequencing-based analysis of mitochondrial DNA characteristics in plasma extracellular vesicles of patients with hepatocellular carcinoma. Oncol Lett. 2020;20:2820-8.
47. Ruhen O, Mirzai B, Clark ME, et al. Comparison of circulating tumour DNA and extracellular vesicle DNA by low-pass whole-genome sequencing reveals molecular drivers of disease in a breast cancer patient. Biomedicines. 2020;9:14.
48. Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156:108-18.e4.
49. Maire CL, Fuh MM, Kaulich K, et al. Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification. Neuro Oncol. 2021;23:1087-99.
50. Németh A, Orgovan N, Sódar BW, et al. Antibiotic-induced release of small extracellular vesicles (exosomes) with surface-associated DNA. Sci Rep. 2017;7:8202.
51. Galbiati S, Damin F, Brambilla D, et al. Small EVs-associated DNA as complementary biomarker to circulating tumor DNA in plasma of metastatic colorectal cancer patients. Pharmaceuticals. 2021;14:128.
52. Hagey DW, Kordes M, Görgens A, et al. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. J Extracell Vesicles. 2021;10:e12142.
53. Zavridou M, Strati A, Bournakis E, Smilkou S, Tserpeli V, Lianidou E. Prognostic significance of gene expression and DNA methylation markers in circulating tumor cells and paired plasma derived exosomes in metastatic castration resistant prostate cancer. Cancers. 2021;13:780.
54. Lee SE, Park HY, Hur JY, et al. Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma. Transl Lung Cancer Res. 2021;10:104-16.
55. Thakur K, Singh MS, Feldstein-Davydova S, Hannes V, Hershkovitz D, Tsuriel S. Extracellular vesicle-derived DNA vs. CfDNA as a biomarker for the detection of colon cancer. Genes. 2021;12:1171.
56. Demuth C, Spindler KG, Johansen JS, et al. Measuring KRAS mutations in circulating tumor DNA by droplet digital PCR and next-generation sequencing. Transl Oncol. 2018;11:1220-4.
57. Wang Y, Zhao Y, Bollas A, Wang Y, Au KF. Nanopore sequencing technology, bioinformatics and applications. Nat Biotechnol. 2021;39:1348-65.
58. Guanzon D, Ross JP, Ma C, Berry O, Liew YJ. Comparing methylation levels assayed in GC-rich regions with current and emerging methods. BMC Genomics. 2024;25:741.
59. Lau BT, Almeda A, Schauer M, et al. Single-molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing. Genome Med. 2023;15:33.
60. van der Pol Y, Tantyo NA, Evander N, et al. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. EMBO Mol Med. 2023;15:e17282.
61. Zhao L, Corvigno S, Ma S, et al. Molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer. Cancers. 2022;14:3589.
62. Werner B, Yuwono N, Duggan J, et al.; INOVATe Investigators. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecol Oncol. 2021;162:720-7.
63. Keserű JS, Soltész B, Lukács J, et al. Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer. J Biotechnol. 2019;298:76-81.
64. Gagliardi S, Mitruccio M, Di Corato R, et al. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells. Cell Commun Signal. 2024;22:165.
65. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.
66. Min L, Wang B, Bao H, et al. Advanced nanotechnologies for extracellular vesicle-based liquid biopsy. Adv Sci. 2021;8:e2102789.
67. Yuana Y, Böing AN, Grootemaat AE, et al. Handling and storage of human body fluids for analysis of extracellular vesicles. J Extracell Vesicles. 2015;4:29260.
68. Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and characterization: toward clinical application. J Clin Invest. 2016;126:1152-62.
69. Shin H, Han C, Labuz JM, et al. High-yield isolation of extracellular vesicles using aqueous two-phase system. Sci Rep. 2015;5:13103.
70. Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2014;3:23430.
71. Karimi N, Cvjetkovic A, Jang SC, et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci. 2018;75:2873-86.
72. Wei R, Zhao L, Kong G, et al. Combination of size-exclusion chromatography and ultracentrifugation improves the proteomic profiling of plasma-derived small extracellular vesicles. Biol Proced Online. 2020;22:12.
73. Johnsen KB, Gudbergsson JM, Andresen TL, Simonsen JB. What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:109-16.
74. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213-28.
75. Ostenfeld MS, Jensen SG, Jeppesen DK, et al. miRNA profiling of circulating EpCAM+ extracellular vesicles: promising biomarkers of colorectal cancer. J Extracell Vesicles. 2016;5:31488.
76. Wang W, Luo J, Wang S. Recent progress in isolation and detection of extracellular vesicles for cancer diagnostics. Adv Healthc Mater. 2018;7:e1800484.
77. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.
78. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170-7.
79. Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5:41-4.
80. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-9.
81. Rani S, Sehgal A, Kaur J, Pandher DK, Punia RS. Osteopontin as a tumor marker in ovarian cancer. J Midlife Health. 2022;13:200-5.
82. Hirsch M, Duffy J, Davis CJ, Plana MN, Khan KS; International Collaboration to Harmonise Outcomes and Measures for Endometriosis. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG. 2016;123:1761-8.
83. Skates SJ, Mai P, Horick NK, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res. 2011;4:1401-8.
84. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355-66.
85. Rani S, Lai A, Nair S, et al. Extracellular vesicles as mediators of cell-cell communication in ovarian cancer and beyond - a lipids focus. Cytokine Growth Factor Rev. 2023;73:52-68.
86. Wendler F, Favicchio R, Simon T, Alifrangis C, Stebbing J, Giamas G. Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene. 2017;36:877-84.
87. Godbole N, Lai A, Carrion F, et al. Extracellular vesicle miRNAs from three-dimensional ovarian cancer in vitro models and their implication in overall cancer survival. Heliyon. 2025;11:e42188.
88. Tresse E, Marturia-Navarro J, Sew WQG, et al. Mitochondrial DNA damage triggers spread of Parkinson’s disease-like pathology. Mol Psychiatry. 2023;28:4902-14.
89. Liaw A, Liu C, Ivanovski S, Han P. The relevance of DNA methylation and histone modification in periodontitis: a scoping review. Cells. 2022;11:3211.
90. Han P, Lai A, Salomon C, Ivanovski S. Detection of salivary small extracellular vesicles associated inflammatory cytokines gene methylation in gingivitis. Int J Mol Sci. 2020;21:5273.
91. Han P, Bartold PM, Salomon C, Ivanovski S. Salivary outer membrane vesicles and DNA methylation of small extracellular vesicles as biomarkers for periodontal status: a pilot study. Int J Mol Sci. 2021;22:2423.
92. Han P, Bartold PM, Ivanovski S. The emerging role of small extracellular vesicles in saliva and gingival crevicular fluid as diagnostics for periodontitis. J Periodontal Res. 2022;57:219-31.
93. Wang J, Liu C, Cutler J, Ivanovski S, Lee RS, Han P. Microbial- and host immune cell-derived extracellular vesicles in the pathogenesis and therapy of periodontitis: a narrative review. J Periodontal Res. 2024;59:1115-29.
94. Rucci C, de Simone G, Salathia S, Casadidio C, Censi R, Bordoni L. Exploring mitochondrial DNA copy number in circulating cell-free DNA and extracellular vesicles across cardiovascular health status: a prospective case-control pilot study. FASEB J. 2024;38:e23672.
95. García-Silva S, Benito-Martín A, Sánchez-Redondo S, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation. J Exp Med. 2019;216:1061-70.
96. Yakubovich EI, Polischouk AG, Evtushenko VI. Principles and problems of exosome isolation from biological fluids. Biochem Suppl Ser A Membr Cell Biol. 2022;16:115-26.
97. Yuana Y, Levels J, Grootemaat A, Sturk A, Nieuwland R. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. J Extracell Vesicles. 2014;3:23262.
98. Chen J, Li P, Zhang T, et al. Review on strategies and technologies for exosome isolation and purification. Front Bioeng Biotechnol. 2021;9:811971.
99. Elzanowska J, Semira C, Costa-Silva B. DNA in extracellular vesicles: biological and clinical aspects. Mol Oncol. 2021;15:1701-14.
100. Herrero C, Ferreirós A, Pérez-Fentes D, et al. Extracellular vesicles’ genetic cargo as noninvasive biomarkers in cancer: a pilot study using ExoGAG technology. Biomedicines. 2023;11:404.
101. Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347-76.
102. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318-22.
103. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86:774-9.
104. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67-71.
105. Barbosa A, Peixoto A, Pinto P, Pinheiro M, Teixeira MR. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. Expert Rev Mol Med. 2018;20:e6.
106. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-65.
107. Mattox AK, Douville C, Wang Y, et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 2023;13:2166-79.
108. LaFramboise WA, Petrosko P, Gallo PH, et al. Cell-free DNA, tumor molecular concordance, and clinical correlates of patients with cancer treated in a large community health care network. J Mol Diagn. 2025;27:882-98.
109. Davidson BA, Miranda AX, Reed SC, et al. An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release. Commun Biol. 2024;7:441.
110. Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van ’t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22:15.
111. Trevisi E, Sessa C, Colombo I. Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities. Explor Target Antitumor Ther. 2024;5:627-40.
112. Guo XM, Miller H, Matsuo K, Roman LD, Salhia B. Circulating cell-free DNA methylation profiles in the early detection of ovarian cancer: a scoping review of the literature. Cancers. 2021;13:838.
113. Buckley DN, Lewinger JP, Gooden G, et al. OvaPrint-A cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer. Clin Cancer Res. 2023;29:5196-206.
114. Lu H, Liu Y, Wang J, et al. Detection of ovarian cancer using plasma cell-free DNA methylomes. Clin Epigenetics. 2022;14:74.
115. Zhou H, Zhang X, Liu Q, et al. Can circulating cell free DNA be a promising marker in ovarian cancer? - a genome-scale profiling study in a single institution. J Ovarian Res. 2023;16:11.
116. Kamat AA, Baldwin M, Urbauer D, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116:1918-25.
117. Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.
118. Breitbach S, Tug S, Helmig S, et al. Direct quantification of cell-free, circulating DNA from unpurified plasma. PLoS One. 2014;9:e87838.
119. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23:707-12.
120. Spinelli M, Zdanowicz JA, Keller I, et al. Hypertensive disorders of pregnancy share common cfDNA methylation profiles. Sci Rep. 2022;12:19837.
121. Janku F, Huang HJ, Pereira DY, et al. A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. Sci Rep. 2021;11:19653.
122. Bronkhorst AJ, Ungerer V, Holdenrieder S. Comparison of methods for the isolation of cell-free DNA from cell culture supernatant. Tumour Biol. 2020;42:1010428320916314.
123. Lucena-Aguilar G, Sánchez-López AM, Barberán-Aceituno C, Carrillo-Ávila JA, López-Guerrero JA, Aguilar-Quesada R. DNA source selection for downstream applications based on DNA quality indicators analysis. Biopreserv Biobank. 2016;14:264-70.
124. Bartels S, Persing S, Hasemeier B, Schipper E, Kreipe H, Lehmann U. Molecular analysis of circulating cell-free DNA from lung cancer patients in routine laboratory practice: a cross-platform comparison of three different molecular methods for mutation detection. J Mol Diagn. 2017;19:722-32.
125. Neuberger EWI, Brahmer A, Ehlert T, et al. Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients. Sci Rep. 2021;11:13581.
126. Alcaide M, Cheung M, Hillman J, et al. Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. Sci Rep. 2020;10:12564.
127. van Ginkel JH, Huibers MMH, van Es RJJ, de Bree R, Willems SM. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer. 2017;17:428.
128. Zhao Y, O’Keefe CM, Hsieh K, et al. Multiplex digital methylation-specific PCR for noninvasive screening of lung cancer. Adv Sci. 2023;10:e2206518.
129. Zhang Q, Hu G, Yang Q, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130:132-9.
130. Alborelli I, Generali D, Jermann P, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis. 2019;10:534.
131. Esposito Abate R, Frezzetti D, Maiello MR, et al. Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls. Cancers. 2020;12:3804.
132. Singh RR. Next-generation sequencing in high-sensitive detection of mutations in tumors: challenges, advances, and applications. J Mol Diagn. 2020;22:994-1007.
133. Jackson PE, Qiaan GS, Friesen MD, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 2001;61:33-5.
134. Tsang JCH, Charoenkwan P, Chow KCK, et al. Mass spectrometry-based detection of hemoglobin E mutation by allele-specific base extension reaction. Clin Chem. 2007;53:2205-9.
135. Chiappetta C, Anile M, Leopizzi M, Venuta F, Della Rocca C. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer. Clin Chim Acta. 2013;425:93-6.
136. Covas Lage LA, Culler HF, Reichert CO, et al. Circulating cell-free DNA (ccfDNA) concentrations measured by capillary electrophoresis: high cost-effectiveness in discriminating DLBCL patients and associations with high tumor burden. Blood. 2023;142:6085.
137. Medina JE, Annapragada AV, Lof P, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discov. 2025;15:105-18.
138. Mazzone PJ, Bach PB, Carey J, et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024;14:2224-42.
139. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691-700.
140. Pritchett MA, Camidge DR, Patel M, et al. Prospective clinical validation of the InVisionFirst-lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non-small-cell lung cancer. JCO Precis Oncol. 2019;3:1-15.
141. Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15:e0237802.
142. García-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127:592-602.
143. Taylor ML, Giacalone AG, Amrhein KD, Wilson RE Jr, Wang Y, Huang X. Nanomaterials for molecular detection and analysis of extracellular vesicles. Nanomaterials. 2023;13:524.
144. Ye S, You Q, Song S, et al. Nanostructures and nanotechnologies for the detection of extracellular vesicle. Adv Biol. 2023;7:e2200201.
145. Picciolini S, Rodà F, Bedoni M, Gualerzi A. Advances in the field of micro- and nanotechnologies applied to extracellular vesicle research: take-home message from ISEV2021. Micromachines. 2021;12:1563.
146. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem Rev. 2018;118:1917-50.
147. Chiang CY, Chen C. Toward characterizing extracellular vesicles at a single-particle level. J Biomed Sci. 2019;26:9.
148. Yang L, Patel KD, Rathnam C, et al. Harnessing the therapeutic potential of extracellular vesicles for biomedical applications using multifunctional magnetic nanomaterials. Small. 2022;18:e2104783.
149. Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19.
151. Dong X, Chi J, Zheng L, et al. Efficient isolation and sensitive quantification of extracellular vesicles based on an integrated ExoID-Chip using photonic crystals. Lab Chip. 2019;19:2897-904.
152. Woo HK, Sunkara V, Park J, et al. Exodisc for rapid, size-selective, and efficient isolation and analysis of nanoscale extracellular vesicles from biological samples. ACS Nano. 2017;11:1360-70.
153. Zhang Y, Deng Z, Lou D, et al. High-efficiency separation of extracellular vesicles from lipoproteins in plasma by agarose gel electrophoresis. Anal Chem. 2020;92:7493-9.
154. Jeong H, Han C, Cho S, Gianchandani Y, Park J. Analysis of extracellular vesicles using coffee ring. ACS Appl Mater Interfaces. 2018;10:22877-82.
155. Jeong H, Shin H, Yi J, et al. Size-based analysis of extracellular vesicles using sequential transfer of an evaporating droplet. Lab Chip. 2019;19:3326-36.
156. Sitar S, Kejžar A, Pahovnik D, et al. Size characterization and quantification of exosomes by asymmetrical-flow field-flow fractionation. Anal Chem. 2015;87:9225-33.
157. Petersen KE, Shiri F, White T, et al. Exosome isolation: cyclical electrical field flow fractionation in low-ionic-strength fluids. Anal Chem. 2018;90:12783-90.
158. Zhang H, Lyden D. Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat Protoc. 2019;14:1027-53.
159. Wunsch BH, Smith JT, Gifford SM, et al. Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nm. Nat Nanotechnol. 2016;11:936-40.
160. Smith JT, Wunsch BH, Dogra N, et al. Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. Lab Chip. 2018;18:3913-25.
161. Hattori Y, Shimada T, Yasui T, Kaji N, Baba Y. Micro- and nanopillar chips for continuous separation of extracellular vesicles. Anal Chem. 2019;91:6514-21.
162. Ibsen SD, Wright J, Lewis JM, et al. Rapid isolation and detection of exosomes and associated biomarkers from plasma. ACS Nano. 2017;11:6641-51.
163. Moore JH, Varhue WB, Su YH, et al. Conductance-based biophysical distinction and microfluidic enrichment of nanovesicles derived from pancreatic tumor cells of varying invasiveness. Anal Chem. 2019;91:10424-31.
164. Wu M, Ouyang Y, Wang Z, et al. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci U S A. 2017;114:10584-9.
165. Lee K, Shao H, Weissleder R, Lee H. Acoustic purification of extracellular microvesicles. ACS Nano. 2015;9:2321-7.
166. Zhao J, Liu C, Li Y, et al. Thermophoretic detection of exosomal microRNAs by nanoflares. J Am Chem Soc. 2020;142:4996-5001.
167. Liu C, Zhao J, Tian F, et al. Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers. Nat Biomed Eng. 2019;3:183-93.
168. Huang M, Yang J, Wang T, et al. Homogeneous, low-volume, efficient, and sensitive quantitation of circulating exosomal PD-L1 for cancer diagnosis and immunotherapy response prediction. Angew Chem Int Ed Engl. 2020;59:4800-5.
169. Liu C, Xu X, Li B, et al. Single-exosome-counting immunoassays for cancer diagnostics. Nano Lett. 2018;18:4226-32.
170. Gao X, Li S, Ding F, et al. Rapid detection of exosomal microRNAs using virus-mimicking fusogenic vesicles. Angew Chem Int Ed Engl. 2019;58:8719-23.
171. Wan Y, Cheng G, Liu X, et al. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. Nat Biomed Eng. 2017;1:0058.
172. Wan Y, Maurer M, He HZ, et al. Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica. Lab Chip. 2019;19:2346-55.
173. Kang YT, Purcell E, Palacios-Rolston C, et al. Isolation and profiling of circulating tumor-associated exosomes using extracellular vesicular lipid-protein binding affinity based microfluidic device. Small. 2019;15:e1903600.
174. Nakai W, Yoshida T, Diez D, et al. A novel affinity-based method for the isolation of highly purified extracellular vesicles. Sci Rep. 2016;6:33935.
175. Xu H, Liao C, Zuo P, Liu Z, Ye BC. Magnetic-based microfluidic device for on-chip isolation and detection of tumor-derived exosomes. Anal Chem. 2018;90:13451-8.
176. Stapane L, Le Roy N, Hincke MT, Gautron J. The glycoproteins EDIL3 and MFGE8 regulate vesicle-mediated eggshell calcification in a new model for avian biomineralization. J Biol Chem. 2019;294:14526-45.
177. Gao F, Jiao F, Xia C, et al. A novel strategy for facile serum exosome isolation based on specific interactions between phospholipid bilayers and TiO2. Chem Sci. 2019;10:1579-88.
178. Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H. Integrated magneto-electrochemical sensor for exosome analysis. ACS Nano. 2016;10:1802-9.
179. Zhang P, Zhou X, Zeng Y. Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. Chem Sci. 2019;10:5495-504.
180. Zhu L, Wang K, Cui J, et al. Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. Anal Chem. 2014;86:8857-64.
181. Jin D, Yang F, Zhang Y, et al. ExoAPP: exosome-oriented, aptamer nanoprobe-enabled surface proteins profiling and detection. Anal Chem. 2018;90:14402-11.
182. Zhang K, Yue Y, Wu S, Liu W, Shi J, Zhang Z. Rapid capture and nondestructive release of extracellular vesicles using aptamer-based magnetic isolation. ACS Sens. 2019;4:1245-51.
183. Zhao Z, McGill J, Gamero-Kubota P, He M. Microfluidic on-demand engineering of exosomes towards cancer immunotherapy. Lab Chip. 2019;19:1877-86.
184. Fang X, Duan Y, Adkins GB, et al. Highly efficient exosome isolation and protein analysis by an integrated nanomaterial-based platform. Anal Chem. 2018;90:2787-95.
185. Zhang P, He M, Zeng Y. Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide/polydopamine coating. Lab Chip. 2016;16:3033-42.
186. Wang Z, Wu HJ, Fine D, et al. Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. Lab Chip. 2013;13:2879-82.
187. Zhang P, Wu X, Gardashova G, et al. Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis. Sci Transl Med. 2020;12:eaaz2878.
188. Poellmann MJ, Nair A, Bu J, Kim JKH, Kimple RJ, Hong S. Immunoavidity-based capture of tumor exosomes using poly(amidoamine) dendrimer surfaces. Nano Lett. 2020;20:5686-92.
189. Dong J, Zhang RY, Sun N, et al. Coupling nanostructured microchips with covalent chemistry enables purification of sarcoma-derived extracellular vesicles for downstream functional studies. Adv Funct Mater. 2020;30:2003237.
190. Sun N, Lee YT, Kim M, et al. Covalent chemistry-mediated multimarker purification of circulating tumor cells enables noninvasive detection of molecular signatures of hepatocellular carcinoma. Adv Mater Technol. 2021;6:2001056.
191. Zhang P, Zhou X, He M, et al. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng. 2019;3:438-51.
192. Mori K, Hirase M, Morishige T, et al. A pretreatment-free, polymer-based platform prepared by molecular imprinting and post-imprinting modifications for sensing intact exosomes. Angew Chem Int Ed Engl. 2019;58:1612-5.
193. Takeuchi T, Mori K, Sunayama H, et al. Antibody-conjugated signaling nanocavities fabricated by dynamic molding for detecting cancers using small extracellular vesicle markers from tears. J Am Chem Soc. 2020;142:6617-24.
194. Oh HJ, Kim J, Park H, Chung S, Hwang DW, Lee DS. Graphene-oxide quenching-based molecular beacon imaging of exosome-mediated transfer of neurogenic miR-193a on microfluidic platform. Biosens Bioelectron. 2019;126:647-56.
195. Tayebi M, Tavakkoli Yaraki M, Yang HY, Ai Y. A MoS2-MWCNT based fluorometric nanosensor for exosome detection and quantification. Nanoscale Adv. 2019;1:2866-72.
196. Cho S, Yang HC, Rhee WJ. Simultaneous multiplexed detection of exosomal microRNAs and surface proteins for prostate cancer diagnosis. Biosens Bioelectron. 2019;146:111749.
197. Lee JH, Luo J, Choi HK, Chueng SD, Lee KB, Choi JW. Functional nanoarrays for investigating stem cell fate and function. Nanoscale. 2020;12:9306-26.
198. Rodrigues M, Richards N, Ning B, Lyon CJ, Hu TY. Rapid lipid-based approach for normalization of quantum-dot-detected biomarker expression on extracellular vesicles in complex biological samples. Nano Lett. 2019;19:7623-31.
199. Pang X, Zhang X, Gao K, et al. Visible light-driven self-powered device based on a straddling nano-heterojunction and bio-application for the quantitation of exosomal RNA. ACS Nano. 2019;13:1817-27.
200. Lyu Y, Cui D, Huang J, Fan W, Miao Y, Pu K. Near-infrared afterglow semiconducting nano-polycomplexes for the multiplex differentiation of cancer exosomes. Angew Chem Int Ed Engl. 2019;58:4983-7.
201. Fan Y, Duan X, Zhao M, et al. High-sensitive and multiplex biosensing assay of NSCLC-derived exosomes via different recognition sites based on SPRi array. Biosens Bioelectron. 2020;154:112066.
202. Yang Q, Cheng L, Hu L, et al. An integrative microfluidic device for isolation and ultrasensitive detection of lung cancer-specific exosomes from patient urine. Biosens Bioelectron. 2020;163:112290.
203. Wang Q, Zou L, Yang X, et al. Direct quantification of cancerous exosomes via surface plasmon resonance with dual gold nanoparticle-assisted signal amplification. Biosens Bioelectron. 2019;135:129-36.
204. Lee J, Kim H, Heo Y, et al. Enhanced paper-based ELISA for simultaneous EVs/exosome isolation and detection using streptavidin agarose-based immobilization. Analyst. 2019;145:157-64.
205. Zhang H, Wang Z, Zhang Q, Wang F, Liu Y. Ti3C2 MXenes nanosheets catalyzed highly efficient electrogenerated chemiluminescence biosensor for the detection of exosomes. Biosens Bioelectron. 2019;124-125:184-90.
206. Zhang H, Wang Z, Wang F, Zhang Y, Wang H, Liu Y. In situ formation of gold nanoparticles decorated Ti3C2 MXenes nanoprobe for highly sensitive electrogenerated chemiluminescence detection of exosomes and their surface proteins. Anal Chem. 2020;92:5546-53.
207. Sun Y, Jin H, Jiang X, Gui R. Assembly of black phosphorus nanosheets and MOF to form functional hybrid thin-film for precise protein capture, dual-signal and intrinsic self-calibration sensing of specific cancer-derived exosomes. Anal Chem. 2020;92:2866-75.
208. Jiang Q, Liu Y, Wang L, Adkins GB, Zhong W. Rapid enrichment and detection of extracellular vesicles enabled by CuS-enclosed microgels. Anal Chem. 2019;91:15951-8.
209. Chen J, Xu Y, Lu Y, Xing W. Isolation and visible detection of tumor-derived exosomes from plasma. Anal Chem. 2018;90:14207-15.
210. Boriachek K, Masud MK, Palma C, et al. Avoiding pre-isolation step in exosome analysis: direct isolation and sensitive detection of exosomes using gold-loaded nanoporous ferric oxide nanozymes. Anal Chem. 2019;91:3827-34.
211. Huang R, He L, Xia Y, et al. A sensitive aptasensor based on a hemin/G-quadruplex-assisted signal amplification strategy for electrochemical detection of gastric cancer exosomes. Small. 2019;15:e1900735.
212. Wu D, Yu Y, Jin D, Xiao MM, Zhang ZY, Zhang GJ. Dual-aptamer modified graphene field-effect transistor nanosensor for label-free and specific detection of hepatocellular carcinoma-derived microvesicles. Anal Chem. 2020;92:4006-15.
213. Wu D, Zhang H, Jin D, et al. Microvesicle detection by a reduced graphene oxide field-effect transistor biosensor based on a membrane biotinylation strategy. Analyst. 2019;144:6055-63.
214. Cheng HL, Fu CY, Kuo WC, et al. Detecting miRNA biomarkers from extracellular vesicles for cardiovascular disease with a microfluidic system. Lab Chip. 2018;18:2917-25.
215. Zhu F, Li D, Ding Q, et al. 2D magnetic MoS2-Fe3O4 hybrid nanostructures for ultrasensitive exosome detection in GMR sensor. Biosens Bioelectron. 2020;147:111787.
216. Wang C, Wang C, Jin D, et al. AuNP-amplified surface acoustic wave sensor for the quantification of exosomes. ACS Sens. 2020;5:362-9.
217. Suthar J, Parsons ES, Hoogenboom BW, Williams GR, Guldin S. Acoustic immunosensing of exosomes using a quartz crystal microbalance with dissipation monitoring. Anal Chem. 2020;92:4082-93.
218. Zheng H, Guan S, Wang X, Zhao J, Gao M, Zhang X. Deconstruction of heterogeneity of size-dependent exosome subpopulations from human urine by profiling N-glycoproteomics and phosphoproteomics simultaneously. Anal Chem. 2020;92:9239-46.
219. He D, Ho SL, Chan HN, et al. Molecular-recognition-based DNA nanodevices for enhancing the direct visualization and quantification of single vesicles of tumor exosomes in plasma microsamples. Anal Chem. 2019;91:2768-75.
220. Chen C, Zong S, Liu Y, et al. Profiling of exosomal biomarkers for accurate cancer identification: combining DNA-PAINT with machine- learning-based classification. Small. 2019;15:e1901014.
221. Ridolfi A, Brucale M, Montis C, et al. AFM-based high-throughput nanomechanical screening of single extracellular vesicles. Anal Chem. 2020;92:10274-82.
222. Tian Y, Ma L, Gong M, et al. Protein profiling and sizing of extracellular vesicles from colorectal cancer patients via flow cytometry. ACS Nano. 2018;12:671-80.
223. Wu D, Yan J, Shen X, et al. Profiling surface proteins on individual exosomes using a proximity barcoding assay. Nat Commun. 2019;10:3854.
224. Pallares RM, Thanh NTK, Su X. Sensing of circulating cancer biomarkers with metal nanoparticles. Nanoscale. 2019;11:22152-71.
225. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61:112-23.
226. Pallares RM, Kong SL, Ru TH, Thanh NT, Lu Y, Su X. A plasmonic nanosensor with inverse sensitivity for circulating cell-free DNA quantification. Chem Commun. 2015;51:14524-7.
227. Pallares RM, Thanh NTK, Su X. Tunable plasmonic colorimetric assay with inverse sensitivity for extracellular DNA quantification. Chem Commun. 2018;54:11260-3.
228. Ito H, Hasegawa K, Hasegawa Y, et al. Silver nanoscale hexagonal column chips for detecting cell-free DNA and circulating nucleosomes in cancer patients. Sci Rep. 2015;5:10455.
229. Ito H, Inoue H, Hasegawa K, et al. Use of surface-enhanced Raman scattering for detection of cancer-related serum-constituents in gastrointestinal cancer patients. Nanomedicine. 2014;10:599-608.
